Salarius Pharmaceuticals has just announced the addition of a new clinical trial site for their study investigating seclidemstat as a treatment for Ewing sarcoma (relapsed or refractory) as well as FET-rearranged sarcomas.
This new trial site is the Fox Chase Cancer Cent in Pennsylvania. Other trial sites are located in Florida, California, Massachusetts, Texas, Ohio, and New York. There are a total of 9 trial sites in the investigation.
All trial sites are active, and the first participants have received the first dose of the treatment. This therapy is a reversible inhibitor taken orally of LSD1. This is an enzyme which has been found to cause progression in many cancers.
The Study
This study is a dose-expansion stage, and there are 3 patient arms. Each aims to investigate the safety and efficacy of the therapy.
Arm 1
The first arm includes 30 individuals diagnosed with Ewing sarcoma. This is a rare, pediatric cancer in the bone. This arm of the trial will utilize both seclidemstat as well as topotecan in combination with cyclophosphamide. In other words, it will evaluate the investigative therapy when used with chemotherapy.
If this arm continues to show positive results, it could lead to more patients having access to seclidemstat earlier on in their cancer journey, as a second and third-line therapy.
Arm 2
The second arm of this trial is investigating the therapy in 15 patients as a single therapy. All participants in this arm of the trial are diagnosed with myxoid liposarcoma.
Arm 3
The third arm of this trial will investigate this therapy as a single therapy in individuals diagnosed with FET-rearranged sarcoma or Ewing-related sarcomas. There will also be a total of 15 patients in this arm. Both of these conditions are very similar to Ewing sarcoma.
Earlier data has shown that this therapy was able to lead to stable disease as well as a prolonged time until progression for FET-rearranged patients.
Looking Forward
Researchers are hopeful that this therapy could prove beneficial for many other cancers, including those with high unmet needs.
They expect to report results from this trial by 2022; however, they hope to update the public sooner.
You can read more about this trial and the investigative therapy’s potential here.
